Manage Your Liver
Q:

World Hepatitis Day 2016 - Focus on long term protection after treatment to achieve a 65% reduction in deaths

World Hepatitis Day 2016 - Focus on long term protection after treatment to achieve a 65% reduction in deaths
A:

The World Health Organization’s strategy on viral hepatitis in 2015 estimated that there would be 1.4 million deaths from hepatitis-related diseases in 2016. The mortality rate is very high and the number of deaths is far greater than the sum of deaths from Malaria and HIV [1]. Therefore, one of the main targets of World Hepatitis Day 2016 is to reduce hepatitis-related deaths by 65% by 2030, through improving vaccination, preventing early-life infection and providing universal access to treatment.

 

A 65% reduction is not an easy target and in order to achieve this target by 2030, there is a key factor that cannot be neglected but was not mentioned above: post-treatment recovery and protection.

 

A recent study stated that even after successful eradication of hepatitis C virus and achieving sustained virologic response (SVR), the risk of hepatocellular carcinoma (HCC) or liver cancer remains [2]. Another research conducted by the University of Barcelona pointed out that after receiving treatment, some hepatitis C patients developed HCC and the progression was very fast. Research suspected that this was due to the immune system, and suggested that hepatitis C patients monitor their condition closely after treatment, especially those who had HCC or liver fibrosis previously[3].

 

These results show that the risk of serious liver diseases remains even after successful treatment. In addition, after eliminating the virus, the liver needs to rely on its self-repair ability to produce new liver cells so that normal liver function can resume. Therefore, enhancing liver recovery and protection is an integral part that should be added to the strategy. In order to reduce the number of deaths caused by hepatitis-related diseases by 65% effectively, post-treatment liver protection measures must be improved to ensure the liver’s longevity and lower the risk of death.

 

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
Chronic liver disease is a serious condition and a leading cause of death among people across the world. The number of liver cancer cases have over took to become the leading cancer since 2014, and fatty liver disease/ NASH is set to become the leading cause of liver transplant in 2020. Protects your liver In the view of this, liver protection to prevent chronic liver disease is quickly becoming more important than ever. So what can we do
A:
ALT and AST are enzymes that are normally predominantly contained within liver cells. If the liver is injured or damaged, the liver cells spill these enzymes into the blood, raising the AST and ALT enzyme levels in the blood, and we can use it as a measurement of liver injury.   What are the differences between ALT and AST? AST is normally found in a variety of tissues including liver, heart, muscle, kidney, and the brain. It is released int
Hit Questions
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Hepatitis C viruses share a common characteristic to other chronic liver diseases; it could damage the patients’ liver cells. Hepatitis C patients should focus on stopping or reducing the damage in the liver, and this focus should be the same for other chronic liver diseases e.g. hepatitis B, fatty liver disease, NASH etc. And this is exactly what YHK can do.   YHK can stop liver cells damage caused by hepatitis viruses, and can repair damaged liver cells, to he
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us